Genstar Capital, a private equity firm, has completed its acquisition of ERT, a global technology-driven provider of health outcomes, in a take-private transaction valued at approximately $400 million.

“As a private company we will continue to serve our customers and enhance our suite of products,” Dr. Jeffrey Litwin, who will continue to lead ERT as CEO, said. “We have been able to grow our company into a global leader, and, with Genstar’s partnership, we will look for creative new ways to grow our business organically and identify new investment opportunities as part of our continued development.”

Robert Weltman, managing director of Genstar, said, “ERT is already the global leader in its sector, yet we believe the company can benefit from our expertise in the pharmaceuticals industry to create positive change that will drive operations at an increased pace. This is a sector we know well, and the added strength of our operating partners and strategic advisory board will help build ERT into a stronger independent platform company.”